Insulet Corp

Early Stage 1 consolidation has stabilized with repaired short-term EMAs and a Momentum Breakout cleared the recent resistance cluster, signaling new demand. However, price is now extended above the rising 9- and 21-period EMAs and is Extreme Overbought, indicating poor timing for immediate entries. We maintain a medium-term bullish bias but will await a corrective pullback into the EMA support zone before engaging.

• ↑Q1 revenue reached $762 M (+30% YoY) driven by Omnipod demand
• ↑International Omnipod 5 launch drove 45% overseas sales growth
• ↓Class action alleges Omnipod safety misrepresentation, adding volatility